RYZB
Price:
$62.49
Market Cap:
$3.75B
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.
Industry
Biotechnology
IPO Date
2023-09-15
Stock Exchange
NASDAQ
Ticker
RYZB
According to RayzeBio, Inc. Common Stock’s latest financial reports and current stock price. The company's current ROE is 82.72%. This represents a change of 3.19% compared to the average of 2.51% of the last 4 quarters.
The mean historical ROE of RayzeBio, Inc. Common Stock over the last ten years is 119.90%. The current 82.72% ROE has changed -31.01% with respect to the historical average. Over the past ten years (40 quarters), RYZB's ROE was at its highest in in the December 2022 quarter at 13.21%. The ROE was at its lowest in in the September 2023 quarter at -3.16%.
Average
119.90%
Median
61.64%
Minimum
53.95%
Maximum
244.12%
Discovering the peaks and valleys of RayzeBio, Inc. Common Stock ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 14.25%
Maximum Annual ROE = 244.12%
Minimum Annual Increase = -77.90%
Minimum Annual ROE = 53.95%
| Year | ROE | Change |
|---|---|---|
| 2022 | 61.64% | 14.25% |
| 2021 | 53.95% | -77.90% |
The current ROE of RayzeBio, Inc. Common Stock (RYZB) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
119.90%
5-year avg
119.90%
10-year avg
119.90%
RayzeBio, Inc. Common Stock’s ROE is greater than CymaBay Therapeutics, Inc. (-64.17%), greater than SpringWorks Therapeutics, Inc. (-51.10%), greater than Mirati Therapeutics, Inc. (-61.91%), less than Opthea Limited (520.65%), greater than Alpine Immune Sciences, Inc. (-12.69%), greater than Morphic Holding, Inc. (-29.08%), greater than MorphoSys AG (-183.80%), greater than Chinook Therapeutics, Inc. (-41.23%), less than Myovant Sciences Ltd. (49.79%), greater than 1Life Healthcare, Inc. (-24.31%),
| Company | ROE | Market cap |
|---|---|---|
| -64.17% | $3.73B | |
| -51.10% | $3.54B | |
| -61.91% | $4.12B | |
| 520.65% | $4.24B | |
| -12.69% | $4.46B | |
| -29.08% | $2.86B | |
| -183.80% | $2.86B | |
| -41.23% | $2.71B | |
| 49.79% | $2.62B | |
| -24.31% | $3.40B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like RayzeBio, Inc. Common Stock using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like RayzeBio, Inc. Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is RayzeBio, Inc. Common Stock's ROE?
How is the ROE calculated for RayzeBio, Inc. Common Stock (RYZB)?
What is the highest ROE for RayzeBio, Inc. Common Stock (RYZB)?
What is the 3-year average ROE for RayzeBio, Inc. Common Stock (RYZB)?
What is the 5-year average ROE for RayzeBio, Inc. Common Stock (RYZB)?
How does the current ROE for RayzeBio, Inc. Common Stock (RYZB) compare to its historical average?